Q/C Technologies Inc SEC Filings

Bruce Bernstein, a director, filed an Initial Statement of Beneficial Ownership reporting an indirect interest in Q/C Technologies, Inc. (QCLS). The form states a beneficial interest in 23 common shares held indirectly through Stormy Monday LLC. It also reports warrants dated 11/17/2020 that expire 05/18/2026 covering 23 underlying common shares with a listed exercise price of $12,360. The transaction date triggering the filing is 09/01/2025 and the form was signed on 10/06/2025. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest as a member of Stormy Monday LLC.

Joshua Silverman, Executive Chairman and Director, reported the immediate grant and vesting of 8,644 Restricted Stock Units (RSUs) on 10/03/2025 for Q/C Technologies, Inc. (QCLS). The RSUs carried a reported price of $0 and vested immediately upon grant, increasing his total beneficial ownership to 8,673 shares following the transaction. The filing was signed on 10/06/2025 and was filed as a single-person Form 4. The entry indicates a non-derivative equity grant that vests on the grant date, which typically aligns executive incentives with shareholder value without an immediate cash outlay by the reporting person.

Q/C Technologies (QCLS) reported an insider equity award. Director Stephen Friscia acquired 2,161 shares of common stock on October 3, 2025, coded as an acquisition at $0 per share. The filing notes the shares arose from a grant of restricted stock units (RSUs) that vested immediately upon grant.

Following this transaction, Friscia’s beneficial ownership stands at 2,161 shares, held directly.

Q/C Technologies (QCLS) reported an insider equity grant. Director and Chief Medical Officer Mitchell Glass acquired 1,080 shares of common stock on October 3, 2025 via a grant of restricted stock units that vested immediately.

The filing lists the transaction price as $0, consistent with an RSU award, and shows 1,080 shares beneficially owned directly following the transaction.

Form 4 shows Billy Joe White, a director of Q/C Technologies, Inc. (ticker QCLS), received a grant of 2,161 Restricted Stock Units (RSUs) that vested immediately on 10/03/2025. The RSUs were recorded at a $0 per-share acquisition price because they were granted as restricted units rather than purchased shares. After the transaction, the reporting person beneficially owns 2,185 shares directly. The Form 4 is signed and dated 10/06/2025.

This filing records an equity compensation event for an insider rather than an open-market purchase or sale; the immediate vesting increases the director’s direct stake by the stated share count and is reportable under Section 16(a).

Gary M. Rauch, listed as Vice President of Finance, reported a change in beneficial ownership of Q/C Technologies, Inc. (QCLS). On 10/03/2025 Mr. Rauch was granted 1,080 restricted stock units that vested immediately and are recorded as common stock with a reported price of $0. Following the reported transaction he beneficially owns 1,080 shares directly. The Form 4 was signed on 10/06/2025. The filing indicates the award was an RSU grant and contains no additional compensation terms, sale, or exercise dates.

Document type: Shelf registration statement on Form S-3 that includes a prospectus summary, plan of distribution and a list of selling stockholders. The filing lists individual and institutional holders with their current shares and maximum shares to be sold.

The schedule shows Pharmacyte Biotech Inc. holding 9,095,638 shares and a reported post‑sale percentage of 69.21% for one entry, several investors listed with 152,582–312,105 shares and multiple entries showing a 4.99% figure. The document also discloses estimated offering expenses including printing and engraving costs, legal fees of $25,000 and accounting fees of $30,000 totaling the stated items. Signatures include the Executive Chairman, Interim Chief Financial Officer and multiple directors. The filing references the year ended December 31, 2024 and a filing date of April 11, 2025.